Proteomic study identified HSP 70kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms

Kazuyasu Fujii, Norihiro Suzuki, Kazuko Ikeda, Toshihisa Hamada, Takenobu Yamamoto, Tadashi Kondo, Keiji Iwatsuki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Histone deacetylase inhibitors (HDACi) demonstrate possible anticancer activities in various malignancies including lymphoid neoplasms. However, the anticancer effects of HDACi are often limited, and combination therapy with other drugs has been undertaken to improve the outcome of patients. Here we conducted proteomic investigation of 33 lymphoid cell lines to identify novel therapeutic targets for enhancing the effects of HDACi. Using the proteomic data in our published 2D-DIGE database, we examined the proteins associated with resistance to valproic acid (VPA). The lymphoid neoplasm cell lines in the database were grouped according to their sensitivity to VPA treatment. A comparative proteomic study of the cell line groups resulted in the identification of 10 protein spots, whose intensity was associated with chemosensitivity. Among the identified proteins, HSPA1A showed higher expression in cell lines with resistance to VPA, and the results were validated by Western blotting. In vitro experiments demonstrated that treatment with KNK-437, an inhibitor of HSPA1A, enhanced the cytotoxic effects of VPA, as well as vorinostat, in the lymphoid neoplasm cell line. Treatment with KNK-437 facilitated the apoptotic effects of VPA. In conclusion, we identified HSPA1A as a possible therapeutic target, in combination with HDACi, for lymphoid neoplasms.

Original languageEnglish
Pages (from-to)1401-1410
Number of pages10
JournalJournal of Proteomics
Volume75
Issue number4
DOIs
Publication statusPublished - Feb 2 2012

Fingerprint

Histone Deacetylase Inhibitors
Valproic Acid
Proteomics
Cells
Cell Line
Neoplasms
Proteins
Lymphocytes
Therapeutics
Two-Dimensional Difference Gel Electrophoresis
Protein Databases
Western Blotting
Databases
Pharmaceutical Preparations
Experiments

Keywords

  • 2D-DIGE
  • Lymphoid neoplasms
  • Proteome database
  • Valproic acid

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Proteomic study identified HSP 70kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms. / Fujii, Kazuyasu; Suzuki, Norihiro; Ikeda, Kazuko; Hamada, Toshihisa; Yamamoto, Takenobu; Kondo, Tadashi; Iwatsuki, Keiji.

In: Journal of Proteomics, Vol. 75, No. 4, 02.02.2012, p. 1401-1410.

Research output: Contribution to journalArticle

Fujii, Kazuyasu ; Suzuki, Norihiro ; Ikeda, Kazuko ; Hamada, Toshihisa ; Yamamoto, Takenobu ; Kondo, Tadashi ; Iwatsuki, Keiji. / Proteomic study identified HSP 70kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms. In: Journal of Proteomics. 2012 ; Vol. 75, No. 4. pp. 1401-1410.
@article{128022eb350c4a8991cd52fade7018e5,
title = "Proteomic study identified HSP 70kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms",
abstract = "Histone deacetylase inhibitors (HDACi) demonstrate possible anticancer activities in various malignancies including lymphoid neoplasms. However, the anticancer effects of HDACi are often limited, and combination therapy with other drugs has been undertaken to improve the outcome of patients. Here we conducted proteomic investigation of 33 lymphoid cell lines to identify novel therapeutic targets for enhancing the effects of HDACi. Using the proteomic data in our published 2D-DIGE database, we examined the proteins associated with resistance to valproic acid (VPA). The lymphoid neoplasm cell lines in the database were grouped according to their sensitivity to VPA treatment. A comparative proteomic study of the cell line groups resulted in the identification of 10 protein spots, whose intensity was associated with chemosensitivity. Among the identified proteins, HSPA1A showed higher expression in cell lines with resistance to VPA, and the results were validated by Western blotting. In vitro experiments demonstrated that treatment with KNK-437, an inhibitor of HSPA1A, enhanced the cytotoxic effects of VPA, as well as vorinostat, in the lymphoid neoplasm cell line. Treatment with KNK-437 facilitated the apoptotic effects of VPA. In conclusion, we identified HSPA1A as a possible therapeutic target, in combination with HDACi, for lymphoid neoplasms.",
keywords = "2D-DIGE, Lymphoid neoplasms, Proteome database, Valproic acid",
author = "Kazuyasu Fujii and Norihiro Suzuki and Kazuko Ikeda and Toshihisa Hamada and Takenobu Yamamoto and Tadashi Kondo and Keiji Iwatsuki",
year = "2012",
month = "2",
day = "2",
doi = "10.1016/j.jprot.2011.11.010",
language = "English",
volume = "75",
pages = "1401--1410",
journal = "Journal of Proteomics",
issn = "1874-3919",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Proteomic study identified HSP 70kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms

AU - Fujii, Kazuyasu

AU - Suzuki, Norihiro

AU - Ikeda, Kazuko

AU - Hamada, Toshihisa

AU - Yamamoto, Takenobu

AU - Kondo, Tadashi

AU - Iwatsuki, Keiji

PY - 2012/2/2

Y1 - 2012/2/2

N2 - Histone deacetylase inhibitors (HDACi) demonstrate possible anticancer activities in various malignancies including lymphoid neoplasms. However, the anticancer effects of HDACi are often limited, and combination therapy with other drugs has been undertaken to improve the outcome of patients. Here we conducted proteomic investigation of 33 lymphoid cell lines to identify novel therapeutic targets for enhancing the effects of HDACi. Using the proteomic data in our published 2D-DIGE database, we examined the proteins associated with resistance to valproic acid (VPA). The lymphoid neoplasm cell lines in the database were grouped according to their sensitivity to VPA treatment. A comparative proteomic study of the cell line groups resulted in the identification of 10 protein spots, whose intensity was associated with chemosensitivity. Among the identified proteins, HSPA1A showed higher expression in cell lines with resistance to VPA, and the results were validated by Western blotting. In vitro experiments demonstrated that treatment with KNK-437, an inhibitor of HSPA1A, enhanced the cytotoxic effects of VPA, as well as vorinostat, in the lymphoid neoplasm cell line. Treatment with KNK-437 facilitated the apoptotic effects of VPA. In conclusion, we identified HSPA1A as a possible therapeutic target, in combination with HDACi, for lymphoid neoplasms.

AB - Histone deacetylase inhibitors (HDACi) demonstrate possible anticancer activities in various malignancies including lymphoid neoplasms. However, the anticancer effects of HDACi are often limited, and combination therapy with other drugs has been undertaken to improve the outcome of patients. Here we conducted proteomic investigation of 33 lymphoid cell lines to identify novel therapeutic targets for enhancing the effects of HDACi. Using the proteomic data in our published 2D-DIGE database, we examined the proteins associated with resistance to valproic acid (VPA). The lymphoid neoplasm cell lines in the database were grouped according to their sensitivity to VPA treatment. A comparative proteomic study of the cell line groups resulted in the identification of 10 protein spots, whose intensity was associated with chemosensitivity. Among the identified proteins, HSPA1A showed higher expression in cell lines with resistance to VPA, and the results were validated by Western blotting. In vitro experiments demonstrated that treatment with KNK-437, an inhibitor of HSPA1A, enhanced the cytotoxic effects of VPA, as well as vorinostat, in the lymphoid neoplasm cell line. Treatment with KNK-437 facilitated the apoptotic effects of VPA. In conclusion, we identified HSPA1A as a possible therapeutic target, in combination with HDACi, for lymphoid neoplasms.

KW - 2D-DIGE

KW - Lymphoid neoplasms

KW - Proteome database

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=84855879102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855879102&partnerID=8YFLogxK

U2 - 10.1016/j.jprot.2011.11.010

DO - 10.1016/j.jprot.2011.11.010

M3 - Article

C2 - 22123078

AN - SCOPUS:84855879102

VL - 75

SP - 1401

EP - 1410

JO - Journal of Proteomics

JF - Journal of Proteomics

SN - 1874-3919

IS - 4

ER -